Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Immunoenzyme Techniques | 1 | 2021 | 448 | 0.73 | Why? |
| Lyme Disease | 3 | 2019 | 102 | 0.37 | Why? |
| Belgium | 10 | 2021 | 2064 | 0.32 | Why? |
| Proviruses | 1 | 2005 | 82 | 0.29 | Why? |
| Borrelia burgdorferi | 2 | 2019 | 31 | 0.23 | Why? |
| Tick Bites | 2 | 2019 | 34 | 0.23 | Why? |
| Forestry | 1 | 2018 | 14 | 0.19 | Why? |
| Immunity, Humoral | 3 | 2021 | 4849 | 0.17 | Why? |
| Antibodies | 2 | 2021 | 846 | 0.17 | Why? |
| HIV-2 | 1 | 2017 | 92 | 0.17 | Why? |
| Kidney Transplantation | 3 | 2021 | 5397 | 0.16 | Why? |
| Antibodies, Viral | 6 | 2021 | 51949 | 0.16 | Why? |
| Reimbursement Mechanisms | 1 | 2019 | 243 | 0.15 | Why? |
| Immunoassay | 3 | 2020 | 4485 | 0.15 | Why? |
| Luminescent Measurements | 1 | 2020 | 924 | 0.14 | Why? |
| DNA, Viral | 1 | 2005 | 2521 | 0.14 | Why? |
| Seroconversion | 2 | 2021 | 2515 | 0.14 | Why? |
| Antibodies, Bacterial | 1 | 2018 | 510 | 0.13 | Why? |
| env Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 386 | 0.13 | Why? |
| Immunoglobulin G | 4 | 2021 | 21571 | 0.13 | Why? |
| Hospitals, Teaching | 1 | 2020 | 1609 | 0.12 | Why? |
| NF-kappa B | 1 | 2017 | 1301 | 0.10 | Why? |
| Polymerase Chain Reaction | 1 | 2005 | 6740 | 0.10 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2005 | 4545 | 0.10 | Why? |
| Ambulatory Care Facilities | 1 | 2020 | 2063 | 0.09 | Why? |
| Seroepidemiologic Studies | 3 | 2019 | 10017 | 0.09 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.09 | Why? |
| Sensitivity and Specificity | 4 | 2020 | 22971 | 0.09 | Why? |
| Hepatitis C | 1 | 2019 | 1514 | 0.08 | Why? |
| Renal Dialysis | 2 | 2021 | 4358 | 0.08 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.08 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.07 | Why? |
| Viral Load | 1 | 2005 | 15850 | 0.07 | Why? |
| Adult | 11 | 2021 | 244371 | 0.06 | Why? |
| Occupational Exposure | 2 | 2020 | 4742 | 0.06 | Why? |
| Immunosuppressive Agents | 1 | 2021 | 6331 | 0.06 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.06 | Why? |
| Antigens, Viral | 1 | 2020 | 6298 | 0.06 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.06 | Why? |
| Postoperative Complications | 1 | 2021 | 5861 | 0.06 | Why? |
| Male | 13 | 2021 | 367725 | 0.06 | Why? |
| Population Surveillance | 1 | 2019 | 4967 | 0.06 | Why? |
| Female | 13 | 2021 | 380317 | 0.06 | Why? |
| Host-Pathogen Interactions | 2 | 2020 | 11041 | 0.05 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2005 | 952 | 0.05 | Why? |
| HIV Infections | 1 | 2005 | 11620 | 0.05 | Why? |
| Young Adult | 5 | 2020 | 93724 | 0.05 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.05 | Why? |
| Ticks | 1 | 2018 | 107 | 0.04 | Why? |
| Tick-Borne Diseases | 1 | 2018 | 68 | 0.04 | Why? |
| Humans | 17 | 2021 | 930598 | 0.04 | Why? |
| Retrospective Studies | 4 | 2021 | 105322 | 0.04 | Why? |
| Aged | 7 | 2021 | 215776 | 0.04 | Why? |
| GPI-Linked Proteins | 1 | 2017 | 317 | 0.04 | Why? |
| Principal Component Analysis | 1 | 2018 | 689 | 0.04 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.04 | Why? |
| Hospitals, Public | 1 | 2020 | 774 | 0.03 | Why? |
| Health Personnel | 2 | 2020 | 29646 | 0.03 | Why? |
| Prevalence | 3 | 2020 | 25773 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Glycoproteins | 1 | 2017 | 615 | 0.03 | Why? |
| Antigens, CD | 1 | 2017 | 984 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2021 | 3395 | 0.03 | Why? |
| Homes for the Aged | 1 | 2021 | 1071 | 0.03 | Why? |
| Graft Rejection | 1 | 2021 | 1766 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Cost of Illness | 1 | 2021 | 1903 | 0.03 | Why? |
| HIV-1 | 1 | 2005 | 3365 | 0.02 | Why? |
| Hepatitis C, Chronic | 1 | 2019 | 973 | 0.02 | Why? |
| Cell Line | 1 | 2005 | 12040 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2005 | 11304 | 0.02 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.02 | Why? |
| Antibody Formation | 1 | 2020 | 4038 | 0.02 | Why? |
| Infant | 2 | 2020 | 30274 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| Antiviral Agents | 1 | 2019 | 41703 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2020 | 9893 | 0.02 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.02 | Why? |
| Kidney Failure, Chronic | 1 | 2021 | 3222 | 0.02 | Why? |
| Transplant Recipients | 1 | 2021 | 4982 | 0.02 | Why? |
| Child, Preschool | 2 | 2020 | 36283 | 0.02 | Why? |
| Nurses | 1 | 2020 | 2285 | 0.02 | Why? |
| Nursing Homes | 1 | 2021 | 4155 | 0.02 | Why? |
| HEK293 Cells | 1 | 2017 | 8394 | 0.02 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.02 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2021 | 8041 | 0.01 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.01 | Why? |
| Child | 2 | 2020 | 70012 | 0.01 | Why? |
| Animals | 2 | 2020 | 78931 | 0.01 | Why? |
| Risk Factors | 2 | 2019 | 71621 | 0.01 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.01 | Why? |
| Hospitals | 1 | 2017 | 11793 | 0.01 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.01 | Why? |
| RNA, Viral | 1 | 2005 | 32276 | 0.01 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.01 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.01 | Why? |
| Prospective Studies | 1 | 2020 | 43301 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.01 | Why? |
Kabamba's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(107)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(60)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_